| Price | 14.33 |
| Price Change Today | -$0.32 (-2.18%) |
| P&P rating | ![]() |
| Zacks Rank | 3 - HOLD |
| Open Price | $14.63 |
| Previous Close | $14.65 |
| Daily Range | $14.25 - $14.63 |
| 52-Week Range | $9.17 - $16.20 |
| Volume | 297,672 |
| ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody. | |





Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment